ESR1 and breast cancer: Therefore, inactivation or removal of NCOA2 can be a new molecular therapy not only against BC bearing K303R mutation which induces S305 phosphorylation and then NCOA2 recruitment to ERα/Fox but also against endocrine-resistant BC in which elevated S305 phosphorylation may enhance NCOA2 recruitment to ERα/Fox.